Mark Eisner
CIK 1834161 · EVP and Chief Medical Officer · last filed 2026-06-26
Mark Eisner is an EVP and Chief Medical Officer who has filed 35 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for JBIO, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$720.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
409 ILLINOIS STREET
SAN FRANCISCO, CA 94158
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JBIO | Director | — | $15.03 | — | $0 | 1 | 2026-06-26 |
| ZURA | Director | — | $4.12 | — | $0 | 2 | 2026-06-22 |
| VIR | EVP and Chief Medical Officer | 155,913 | $10.38 | $1.62M | -$106.3K | 5 | 2026-02-26 |
| KYNTRA BIO, INC. (FGEN) Delisted | EVP, Chief Medical Officer | 6,397 | $9.75 | $62.4K | -$614.3K | 19 | 2023-09-08 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | JBIO | Grant (A) | — | $0 | EDGAR |
| 2026-06-22 | ZURA | Grant (A) | — | $0 | EDGAR |
| 2026-04-30 | VIR | Notice (144) | −88,958 | -$916.3K | EDGAR |
| 2026-02-26 | VIR | Sell (S) | −3,505 | -$34.0K | EDGAR |
| 2026-02-25 | VIR | Notice (144) | −1,889 | -$18.5K | EDGAR |
| 2026-02-24 | VIR | Notice (144) | −1,616 | -$15.4K | EDGAR |
| 2026-02-24 | ZURA | Grant (A) | — | $0 | EDGAR |
| 2026-02-24 | VIR | Mixed | +52,911 | -$15.6K | EDGAR |
| 2026-02-23 | VIR | Notice (144) | −2,089 | -$15.6K | EDGAR |
| 2025-07-17 | VIR | Notice (144) | −3,586 | -$19.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.